WO2003103704A3 - Proteines impliquees dans la regulation de l'homeostasie energetique - Google Patents

Proteines impliquees dans la regulation de l'homeostasie energetique Download PDF

Info

Publication number
WO2003103704A3
WO2003103704A3 PCT/EP2003/006080 EP0306080W WO03103704A3 WO 2003103704 A3 WO2003103704 A3 WO 2003103704A3 EP 0306080 W EP0306080 W EP 0306080W WO 03103704 A3 WO03103704 A3 WO 03103704A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulation
energy homeostasis
proteins involved
proteins
homeostasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/006080
Other languages
English (en)
Other versions
WO2003103704A2 (fr
Inventor
Karsten Eulenberg
Martin Meise
Guenter Broenner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen AG
Original Assignee
Develogen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen AG filed Critical Develogen AG
Priority to AU2003274715A priority Critical patent/AU2003274715A1/en
Publication of WO2003103704A2 publication Critical patent/WO2003103704A2/fr
Publication of WO2003103704A3 publication Critical patent/WO2003103704A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des nouvelles utilisations de protéines régulant l'homéostasie énergétique et de polynucléotides codant ces protéines pour le diagnostic, l'étude, la prévention et le traitement de maladies et de troubles du métabolisme.
PCT/EP2003/006080 2002-06-10 2003-06-10 Proteines impliquees dans la regulation de l'homeostasie energetique Ceased WO2003103704A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003274715A AU2003274715A1 (en) 2002-06-10 2003-06-10 L(2)44 dea, wunen-2, grapes, cg2221, cg1172, rutabaga, cg11940, facl involved in the regulation of energy homeostasis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02012843.5 2002-06-10
EP02012843 2002-06-10
EP02013329 2002-06-18
EP02013329.4 2002-06-18

Publications (2)

Publication Number Publication Date
WO2003103704A2 WO2003103704A2 (fr) 2003-12-18
WO2003103704A3 true WO2003103704A3 (fr) 2004-04-15

Family

ID=29737926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006080 Ceased WO2003103704A2 (fr) 2002-06-10 2003-06-10 Proteines impliquees dans la regulation de l'homeostasie energetique

Country Status (2)

Country Link
AU (1) AU2003274715A1 (fr)
WO (1) WO2003103704A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1218314A1 (zh) * 2013-06-28 2017-02-10 Acumen Research Laboratories Pte. Ltd. 脓毒症生物标志物及其应用
CN112618703A (zh) * 2020-12-24 2021-04-09 上海交通大学医学院附属瑞金医院 Acsl4作为制备2型糖尿病药物的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067637A1 (fr) * 1998-06-25 1999-12-29 Merck Patent Gmbh Utilisation de recepteurs de la famille rev-erb pour le criblage
WO2000006087A2 (fr) * 1998-07-29 2000-02-10 Tularik Inc. Proteine-2 (ucp2) dissociante: compositions et procedes d'utilisation
WO2001018210A1 (fr) * 1999-09-08 2001-03-15 Genentech, Inc. Acides nucleiques et polypeptides du facteur 19 de croissance du fibroblaste, et procedes d'utilisation dans le traitement de l'obesite
WO2001066706A1 (fr) * 2000-03-03 2001-09-13 Human Genome Sciences, Inc. Polynucleotides et polypeptides de la proteine tyrosine phosphatase, et anticorps
WO2001096371A2 (fr) * 2000-06-16 2001-12-20 Develogen Ag Gene lie a l'adipose
WO2002005810A1 (fr) * 2000-07-18 2002-01-24 Joslin Diabetes Center Modulation de la monoxyde d'azote synthase par la proteine kinase c

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067637A1 (fr) * 1998-06-25 1999-12-29 Merck Patent Gmbh Utilisation de recepteurs de la famille rev-erb pour le criblage
WO2000006087A2 (fr) * 1998-07-29 2000-02-10 Tularik Inc. Proteine-2 (ucp2) dissociante: compositions et procedes d'utilisation
WO2001018210A1 (fr) * 1999-09-08 2001-03-15 Genentech, Inc. Acides nucleiques et polypeptides du facteur 19 de croissance du fibroblaste, et procedes d'utilisation dans le traitement de l'obesite
WO2001066706A1 (fr) * 2000-03-03 2001-09-13 Human Genome Sciences, Inc. Polynucleotides et polypeptides de la proteine tyrosine phosphatase, et anticorps
WO2001096371A2 (fr) * 2000-06-16 2001-12-20 Develogen Ag Gene lie a l'adipose
WO2002005810A1 (fr) * 2000-07-18 2002-01-24 Joslin Diabetes Center Modulation de la monoxyde d'azote synthase par la proteine kinase c

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200011, Derwent World Patents Index; Class B04, AN 2000-126652, XP002261387 *
DATABASE WPI Section Ch Week 200017, Derwent World Patents Index; Class B04, AN 2000-195157, XP002261390 *
DATABASE WPI Section Ch Week 200163, Derwent World Patents Index; Class B04, AN 2001-565582, XP002261391 *
DATABASE WPI Section Ch Week 200214, Derwent World Patents Index; Class B04, AN 2002-106464, XP002261389 *
DATABASE WPI Section Ch Week 200217, Derwent World Patents Index; Class B04, AN 2002-130151, XP002261388 *
DATABASE WPI Section Ch Week 200224, Derwent World Patents Index; Class B04, AN 2002-188506, XP002261392 *

Also Published As

Publication number Publication date
WO2003103704A2 (fr) 2003-12-18
AU2003274715A1 (en) 2003-12-22
AU2003274715A8 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
MA29409B1 (fr) Anticorps diriges contre le peptide amyloïde -beta, et methodes pour leurs utilisations
EP1357908A4 (fr) Acyl-sulfamides pour le traitement de l'obesite, du diabete et des troubles lipidiques
MA29836B1 (fr) Proteines de fusion avec l'albumine
WO2005076819A3 (fr) Chlorite dans le traitement de maladie neurodegenerative
EP1711510A4 (fr) Therapeutique par des agents rnai appliquee dans le traitement de maladies oculaires resultant d'une neovascularisation
NO20082216L (no) Terapeutisk vaksine
EP1551369A4 (fr) Therapie de combinaison pour le traitement de troubles fibrosants
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
MA32300B1 (fr) Anticorps anti-facteur d humanises et utilisations de ceux-ci
WO2002046222A3 (fr) Compositions et procede de diagnostic de la maladie d'alzheimer
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
EP1711197A4 (fr) Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
MA27592A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
WO2003105781A3 (fr) Compositions ophtalmiques destinees a traiter l'hypertension oculaire
EP1178796A4 (fr) Sels de carboxamide d'aminoimidazole utiles dans la prevention et le traitement des maladies du foie
WO2003103704A3 (fr) Proteines impliquees dans la regulation de l'homeostasie energetique
EP3893890A4 (fr) Ginsénoside m1 utilisé en tant que modulateur d'enzymes de régulation de l'angiotensine et son utilisation pour le traitement de maladies ou d'états comprenant des symptômes provoqués par un coronavirus
ATE545428T1 (de) Pik4cb involviert in der regulierung des energiestoffwechsels
WO2003066086A3 (fr) Proteines intervenant dans la regulation de l'homeostase energetique
WO2004035082A3 (fr) Proteines impliquees dans la regulation de l'homeostasie energetique
WO2003092715A3 (fr) Proteines impliquees dans la regulation de l'homeostasie energetique
WO2004020465A3 (fr) Proteines intervenant dans la regulation de l'homeostasie energetique
DE60309850D1 (de) Cg8327 und srm in der regulation von energie-homeostase
WO2003005034A3 (fr) Procedes d'identification d'agents therapeutiques de traitement de maladies impliquant le gene
FR2707166B1 (fr) Utilisation de l'efaroxan et de ses dérivés pour la fabrication de médicaments destinés au traitement de maladies neurodégénératives et leur progression .

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP